JP2017535612A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535612A5
JP2017535612A5 JP2017545857A JP2017545857A JP2017535612A5 JP 2017535612 A5 JP2017535612 A5 JP 2017535612A5 JP 2017545857 A JP2017545857 A JP 2017545857A JP 2017545857 A JP2017545857 A JP 2017545857A JP 2017535612 A5 JP2017535612 A5 JP 2017535612A5
Authority
JP
Japan
Prior art keywords
nasal
disorder
preparation
riluzole
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061106 external-priority patent/WO2016081466A1/en
Publication of JP2017535612A publication Critical patent/JP2017535612A/ja
Publication of JP2017535612A5 publication Critical patent/JP2017535612A5/ja
Pending legal-status Critical Current

Links

JP2017545857A 2014-11-21 2015-11-17 リルゾールの舌下投与 Pending JP2017535612A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
US62/083,068 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (2)

Publication Number Publication Date
JP2017535612A JP2017535612A (ja) 2017-11-30
JP2017535612A5 true JP2017535612A5 (enExample) 2018-11-01

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545857A Pending JP2017535612A (ja) 2014-11-21 2015-11-17 リルゾールの舌下投与

Country Status (14)

Country Link
US (1) US20180153862A1 (enExample)
EP (1) EP3220890A1 (enExample)
JP (1) JP2017535612A (enExample)
KR (1) KR20170137030A (enExample)
CN (1) CN107735077A (enExample)
AU (1) AU2015350142A1 (enExample)
BR (1) BR112017010440A2 (enExample)
CA (1) CA2967659A1 (enExample)
EA (1) EA201791110A1 (enExample)
IL (1) IL252283A0 (enExample)
MX (1) MX2017006454A (enExample)
PH (1) PH12017500933A1 (enExample)
SG (1) SG11201703897SA (enExample)
WO (1) WO2016081466A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
HUE046869T2 (hu) 2014-11-21 2020-04-28 Biohaven Therapeutics Ltd Riluzol szublingvális formulációja
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN109963559A (zh) * 2016-09-15 2019-07-02 皮肤科技生命科学有限公司 舌下或颊部施用dim以治疗皮肤病
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
US10235998B1 (en) * 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
CA3096545A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
US12364687B2 (en) * 2018-05-27 2025-07-22 Biohaven Therapeutics Ltd. Use of riluzole oral disintegrating tablets for treating diseases
KR20210045423A (ko) * 2018-08-16 2021-04-26 바이오하벤 테라퓨틱스 리미티드 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
EP1187612B1 (en) * 1999-06-04 2005-01-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US10272082B2 (en) * 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
IN2014DN07989A (enExample) * 2012-03-01 2015-05-01 Pharnext

Similar Documents

Publication Publication Date Title
JP2017535613A5 (enExample)
Jee et al. Impact of sleep disorder as a risk factor for dementia in men and women
Mischoulon et al. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence
MacFarlane et al. Hypnotics in insomnia: the experience of zolpidem
JP2006506378A5 (enExample)
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
Almikhlafi The role of exercise in Parkinson’s Disease
JP2017526693A5 (enExample)
Winkelman et al. Current patterns and future directions in the treatment of insomnia
CN104127730A (zh) 一种治疗神经衰弱的中药及其制备方法
Shinde et al. Homoeopathy for post COVID 19 illnesses: A case series
CN109069466A (zh) 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病
Jung et al. The Effect of Laughter Therapy on Sleep in the Community-dwelling Elderly.
CN103656380A (zh) 一种治疗帕金森病的药物
CN105079350A (zh) 治疗失眠症的中药组合物
CN208211856U (zh) 连体颈舒枕
CN101439154A (zh) 用于治疗失眠的天麻药物
CN101391021B (zh) 一种中药组合物在制备治疗焦虑症药物中的应用
CN110680880A (zh) 一种治疗肝阳上亢型失眠的中药组合物及其用途
CN106177761B (zh) 一种抗抑郁的中药组方及其制品
D’yakonov et al. Comparative studies of the efficacy of combinations of SSRI antidepressants and antipsychotics in the treatment of recurrent depressive disorder
Hajilou Review of Different Applications of Sildenafil with the Focus on its Role in Alzheimer's Disease
Kalko et al. Potential risks and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality
Bakhrushina et al. THE RELEVANCE OF THE PHARMACEUTICAL DEVELOPMENT OF THE NEW DOSAGE FORMS OF HOPANTENIC ACID
ES2969657T3 (es) Tratamiento de trastorno de síndrome postraumático